Grail, the Illumina spinout backed by Bristol-Myers Squibb, Celgene, Merck & Co, Johnson & Johnson, Varian, McKesson, Amazon and Tencent, has agreed to merge with Cirina.
Grail, a US-based cancer diagnostics spinout of genomics technology provider Illumina, has agreed to merge with China-based cancer testing technology developer Cirina.
Launched by Illumina in January 2016, Grail is working on technology that will combine high-intensity sequencing, population-scale clinical testing and data science technology to detect cancer earlier, when it is easier to treat.
Founded in 2014, Cirina is developing blood-plasma tests to detect a range of diseases, and disclosed $12m in series A funding in October 2016. Investment…
